GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » Shares Buyback Ratio %

OTLK (Outlook Therapeutics) Shares Buyback Ratio % : -80.95 (As of Dec. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Outlook Therapeutics's current shares buyback ratio was -80.95%.

Outlook Therapeutics Shares Buyback Ratio % Historical Data

The historical data trend for Outlook Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Shares Buyback Ratio % Chart

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -216.92 -344.54 -38.75 -28.82 -14.49

Outlook Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -0.60 - -69.16 -6.33

Outlook Therapeutics Shares Buyback Ratio % Calculation

Outlook Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2022 ) - Shares Outstanding (EOP) (A: Sep. 2023 )) / Shares Outstanding (EOP) (A: Sep. 2022 )
=(11.3655 - 13.0129) / 11.3655
=-14.49%

Outlook Therapeutics's Shares Buyback Ratio for the quarter that ended in Jun. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2024 )) / Shares Outstanding (EOP) (A: Mar. 2024 )
=(22.0128 - 23.4056) / 22.0128
=-6.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » Shares Buyback Ratio %
Comparable Companies
VOR BIVI NVCT GRPH FHTX RIGL RPTX VRCA CYDY MRSN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
41O:Germany
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Website
https://www.outlooktherapeutics.com
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Executives
Lawrence A Kenyon officer: CFO and Secretary C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin director ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Jeff Evanson officer: Chief Commercial Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Terry Dagnon officer: Chief Operating Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Faisal Ghiath Sukhtian director 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger director 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii director, officer: CEO and President 1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian director, 10 percent owner 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Syntone Ventures Llc 10 percent owner 1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang director C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth director C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments director C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007